Compare Hilton Hotels Corporation Common Stock (HLT) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $322.66 (market cap $72.59B), while Inovio Pharmaceuticals Inc trades at $0.9 (market cap $78.67M). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 922.7× Inovio Pharmaceuticals Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| HLT | INO | |
|---|---|---|
Market Cap | $72.59B | $78.67M |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $2.87 |
52-Week Low | $256.75 | $0.66 |
Enterprise Value | $85.60B | $50.00M |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $323.16, up 3.91% over 24 hours, with a bullish analyst consensus of 57% buy ratings and a $352 price target. Recent earnings have consistently beaten estimates, with Q2 2026 EPS at $2.29 matching expectations. The stock shows bearish technical signals but strong fundamentals, including revenue growth to $12.04B in 2025 and a net income margin of 12.69%. However, rising debt levels and a high P/E ratio of 46.21 pose valuation concerns.
The outlook for HLT is positive due to robust travel demand and a growing hotel pipeline, though premium valuation and increasing debt require caution. Investment opportunity lies in sustained earnings growth and capital returns, while risks include economic sensitivity and labor disputes, as highlighted by ongoing strikes and soft Q3 guidance affecting investor sentiment.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
